Overview
The world's healthcare champions — US pharma and devices beside Novo Nordisk, Roche, Novartis and AstraZeneca, around 125 companies.
Top Holdings
| Ticker | Holding | Weight |
|---|---|---|
| LLY | Eli Lilly & Co. | 9.8% |
| JNJ | Johnson & Johnson | 6.4% |
| ABBV | AbbVie Inc. | 5.2% |
| NOVO-B | Novo Nordisk | 4.4% |
| AZN | AstraZeneca | 3.9% |
| NOVN | Novartis AG | 3.7% |
| ROG | Roche Holding | 3.4% |
| MRK | Merck & Co. | 3.2% |
| ABT | Abbott Laboratories | 3.1% |
| UNH | UnitedHealth Group | 2.9% |
Fund Details
Investment Thesis
The obesity-drug duopoly is split across two continents — Lilly in Indianapolis, Novo in Copenhagen — and IXJ is the one sector fund that owns both at full weight, plus Europe's pharma giants trading cheaper than their US peers. The +16% year rode the sector's rehabilitation as drug-pricing fears faded. Healthcare demand is the closest thing equities have to a demographic certainty.
Who It's For
Healthcare allocators who want the global industry rather than its American half — the structural upgrade over XLV for the GLP-1 era and beyond.
10-Year History
| Year | Close | % Chg |
|---|---|---|
| 2016 | $49.71 | -- |
| 2017 | $58.65 | +18.0% |
| 2018 | $58.65 | +0.0% |
| 2019 | $70.97 | +21.0% |
| 2020 | $79.49 | +12.0% |
| 2021 | $93.00 | +17.0% |
| 2022 | $85.56 | -8.0% |
| 2023 | $87.27 | +2.0% |
| 2024 | $87.27 | +0.0% |
| 2025 | $96.00 | +10.0% |
| Year | Yield |
|---|---|
| 2016 | 1.80% |
| 2017 | 1.70% |
| 2018 | 1.80% |
| 2019 | 1.70% |
| 2020 | 1.50% |
| 2021 | 1.30% |
| 2022 | 1.60% |
| 2023 | 1.70% |
| 2024 | 1.60% |
| 2025 | 1.50% |
| Year | AUM | % Chg |
|---|---|---|
| 2016 | $1.5B | -- |
| 2017 | $1.8B | +20.0% |
| 2018 | $2B | +11.1% |
| 2019 | $2.5B | +25.0% |
| 2020 | $3B | +20.0% |
| 2021 | $3.8B | +26.7% |
| 2022 | $3.5B | -7.9% |
| 2023 | $3.5B | +0.0% |
| 2024 | $3.8B | +8.6% |
| 2025 | $4B | +5.3% |
Price history from exchange data. Dividend yields from reported distributions; some earlier years are derived from total-return vs price-return data or are ETFHub estimates. AUM history is an ETFHub estimate modelled from current assets and annual returns (fund flows not reflected) and may differ from official fund records. Data as of October 2026.
Related US Sectors ETFs
Markets. Intelligence. Daily.
Full briefs on 400+ ETFs, curated daily ETF news, and a free weekly deep-dive newsletter — all on ETFHub.
Get the Free Weekly Brief Explore the ETF Portal Official Fund Page →